Cargando…

The Plasma Level of Interleukin-1β Can Be a Biomarker of Angiopathy in Systemic Chronic Active Epstein–Barr Virus Infection

Systemic chronic active Epstein–Barr virus infection (sCAEBV) is an EBV-positive T- or NK-cell neoplasm revealing persistent systemic inflammation. Twenty-five percent of sCAEBV patients accompany angiopathy. It is crucial to clarify the mechanisms of angiopathy development in sCAEBV because angiopa...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohashi, Ayaka, Uemura, Yu, Yoshimori, Mayumi, Wada, Naomi, Imadome, Ken-Ichi, Yudo, Kazuo, Koyama, Takatoshi, Shimizu, Norio, Nishio, Miwako, Arai, Ayako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019545/
https://www.ncbi.nlm.nih.gov/pubmed/35464987
http://dx.doi.org/10.3389/fmicb.2022.874998
_version_ 1784689308619243520
author Ohashi, Ayaka
Uemura, Yu
Yoshimori, Mayumi
Wada, Naomi
Imadome, Ken-Ichi
Yudo, Kazuo
Koyama, Takatoshi
Shimizu, Norio
Nishio, Miwako
Arai, Ayako
author_facet Ohashi, Ayaka
Uemura, Yu
Yoshimori, Mayumi
Wada, Naomi
Imadome, Ken-Ichi
Yudo, Kazuo
Koyama, Takatoshi
Shimizu, Norio
Nishio, Miwako
Arai, Ayako
author_sort Ohashi, Ayaka
collection PubMed
description Systemic chronic active Epstein–Barr virus infection (sCAEBV) is an EBV-positive T- or NK-cell neoplasm revealing persistent systemic inflammation. Twenty-five percent of sCAEBV patients accompany angiopathy. It is crucial to clarify the mechanisms of angiopathy development in sCAEBV because angiopathy is one of the main causes of death. Interleukin-1β (IL-1β) is reported to be involved in angiopathy onset. We investigated if IL-1β plays a role as the inducer of angiopathy of sCAEBV. We detected elevated IL-1β levels in four out of 17 sCAEBV patient’s plasma. Interestingly, three out of the four had clinically associated angiopathy. None of the other patients with undetectable level of IL-1β had angiopathy. In all patients with high plasma levels of IL-1β and vascular lesions, EBV-infected cells were CD4-positive T cells. In one patient with high plasma IL-1β, the level of IL-1β mRNA of the monocytes was 17.2 times higher than the level of the same patient’s EBV-infected cells in peripheral blood. In Ea.hy926 cells, which are the models of vascular endothelial cells, IL-1β inhibited the proliferation and induced the surface coagulation activity. IL-1β is a potent biomarker and a potent therapeutic target to treat sCAEBV accompanying angiopathy.
format Online
Article
Text
id pubmed-9019545
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90195452022-04-21 The Plasma Level of Interleukin-1β Can Be a Biomarker of Angiopathy in Systemic Chronic Active Epstein–Barr Virus Infection Ohashi, Ayaka Uemura, Yu Yoshimori, Mayumi Wada, Naomi Imadome, Ken-Ichi Yudo, Kazuo Koyama, Takatoshi Shimizu, Norio Nishio, Miwako Arai, Ayako Front Microbiol Microbiology Systemic chronic active Epstein–Barr virus infection (sCAEBV) is an EBV-positive T- or NK-cell neoplasm revealing persistent systemic inflammation. Twenty-five percent of sCAEBV patients accompany angiopathy. It is crucial to clarify the mechanisms of angiopathy development in sCAEBV because angiopathy is one of the main causes of death. Interleukin-1β (IL-1β) is reported to be involved in angiopathy onset. We investigated if IL-1β plays a role as the inducer of angiopathy of sCAEBV. We detected elevated IL-1β levels in four out of 17 sCAEBV patient’s plasma. Interestingly, three out of the four had clinically associated angiopathy. None of the other patients with undetectable level of IL-1β had angiopathy. In all patients with high plasma levels of IL-1β and vascular lesions, EBV-infected cells were CD4-positive T cells. In one patient with high plasma IL-1β, the level of IL-1β mRNA of the monocytes was 17.2 times higher than the level of the same patient’s EBV-infected cells in peripheral blood. In Ea.hy926 cells, which are the models of vascular endothelial cells, IL-1β inhibited the proliferation and induced the surface coagulation activity. IL-1β is a potent biomarker and a potent therapeutic target to treat sCAEBV accompanying angiopathy. Frontiers Media S.A. 2022-04-06 /pmc/articles/PMC9019545/ /pubmed/35464987 http://dx.doi.org/10.3389/fmicb.2022.874998 Text en Copyright © 2022 Ohashi, Uemura, Yoshimori, Wada, Imadome, Yudo, Koyama, Shimizu, Nishio and Arai. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Ohashi, Ayaka
Uemura, Yu
Yoshimori, Mayumi
Wada, Naomi
Imadome, Ken-Ichi
Yudo, Kazuo
Koyama, Takatoshi
Shimizu, Norio
Nishio, Miwako
Arai, Ayako
The Plasma Level of Interleukin-1β Can Be a Biomarker of Angiopathy in Systemic Chronic Active Epstein–Barr Virus Infection
title The Plasma Level of Interleukin-1β Can Be a Biomarker of Angiopathy in Systemic Chronic Active Epstein–Barr Virus Infection
title_full The Plasma Level of Interleukin-1β Can Be a Biomarker of Angiopathy in Systemic Chronic Active Epstein–Barr Virus Infection
title_fullStr The Plasma Level of Interleukin-1β Can Be a Biomarker of Angiopathy in Systemic Chronic Active Epstein–Barr Virus Infection
title_full_unstemmed The Plasma Level of Interleukin-1β Can Be a Biomarker of Angiopathy in Systemic Chronic Active Epstein–Barr Virus Infection
title_short The Plasma Level of Interleukin-1β Can Be a Biomarker of Angiopathy in Systemic Chronic Active Epstein–Barr Virus Infection
title_sort plasma level of interleukin-1β can be a biomarker of angiopathy in systemic chronic active epstein–barr virus infection
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019545/
https://www.ncbi.nlm.nih.gov/pubmed/35464987
http://dx.doi.org/10.3389/fmicb.2022.874998
work_keys_str_mv AT ohashiayaka theplasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection
AT uemurayu theplasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection
AT yoshimorimayumi theplasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection
AT wadanaomi theplasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection
AT imadomekenichi theplasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection
AT yudokazuo theplasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection
AT koyamatakatoshi theplasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection
AT shimizunorio theplasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection
AT nishiomiwako theplasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection
AT araiayako theplasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection
AT ohashiayaka plasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection
AT uemurayu plasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection
AT yoshimorimayumi plasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection
AT wadanaomi plasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection
AT imadomekenichi plasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection
AT yudokazuo plasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection
AT koyamatakatoshi plasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection
AT shimizunorio plasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection
AT nishiomiwako plasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection
AT araiayako plasmalevelofinterleukin1bcanbeabiomarkerofangiopathyinsystemicchronicactiveepsteinbarrvirusinfection